Top Consumer Service Stocks To Own For 2015

Top Consumer Service Stocks To Own For 2015: GlaxoSmithKline PLC(GSK)

GlaxoSmithKline plc, together with its subsidiaries, engages in the discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health-related consumer products worldwide. It offers pharmaceutical products in various therapeutic areas comprising respiratory, HIV, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, oncology and emesis, vaccines, and dermatologicals. The company provides prescription medicines to treat a range of conditions, including infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer. It also markets a range of vaccines to prevent life-threatening or crippling illnesses, such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza, and bacterial meningitis. In addition, the company provides OTC medicines, including Panadol, a paracetamol-based treatment of headache and joi nt pain, fever, and cold symptoms; Gaviscon, a range of antacid products that relieve heartburn due to acid reflux; and NicoDerm, NiQuitin CQ, Nicabate, and Nicorette for the treatment of nicotine withdrawal as an aid to quit smoking. Further, it offers oral healthcare products comprising Sensodyne, a range of toothpastes and toothbrushes for the prevention of dental sensitivity; Aquafresh, a range of toothpastes, toothbrushes, and mouthwashes; and Polident, Poligrip, and Corega, which are denture adhesives and cleansers. Additionally, the company provides nutritional healthcare products consisting of Lucozade, an energy and sports drinks for energy and hydration; Horlicks, a malted, milk-based drink and food for nutrition application; and Ribena, an apple, orange, raspberry, and pomegranate flavored fruit drink, as well as markets skincare products. GlaxoSmithKl! ine plc was incorporated in 1999 and is headquartered in Brentford, United Kingdom.

Advisors' Opinion:

• [By Motley Fool Staff]

  George Budwell: One of the most disappointing clinical failures to me was GlaxoSmithKline's (NYSE: GSK  ) cancer vaccine candidate, MAGE-A3. Last March, we learned that MAGE-A3 failed to improve disease-free survival (DFS), compared to placebo, in non-small cell lung cancer patients, making it the latest in a long line of high profile clinical failures for vaccines aimed at treating cancer. In 2013, MAGE-A3 also flamed out as a potential treatment for skin cancer.

• [By Motley Fool Staff]

  If Avanir wins the FDA go-ahead for AVP-825 it could win away share from oral sumatriptan tablets, which are the most commonly prescribed medicine for acute migraines. Prior to losing patent protection, sumatriptan, sold as Imitrex by GlaxoSmithKline (NYSE: GSK  ) , had sales of more than $1 billion annually.

• [By Brian Orelli]

  Of course, Seattle Genetics is more than just Adcetris. The drug is built on its antibody drug conjugate technology, which the biotech has licensed to 12 different companies, including Genmab, which signed up for a second collaboration in September. During the quarter, three of the collaborators -- GlaxoSmithKline (NYSE: GSK  ) , Takeda, and Bayer -- moved drugs along in the clinic, triggering milestone payments.

• [By Ben Levisohn]

  Biotech companies that are most likely to benefit because they are “Ahead in clinical development and/or have established relationships with [the Biomedical Advanced Research and Development Authority, or] BARDA which may facilitate getting a contract” include GlaxoSmithKline (GSK), NewLink Genetics (NLNK), Johnson & Johnson (JNJ) and Chimerix (CMRX). Kantor includes Tekmira (TKMR) and Sarepta (SRPT) among “companies with viable programs” that are “moving forward and lik! ely to at! tract additional funding.”

source from Top Stocks For 2015:http://www.topstocksblog.com/top-consumer-service-stocks-to-own-for-2015-2.html